未登录

J

Julie M. Roda

University System of Ohio

H指数:19

被引数:1,703

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Combination targeting of myeloid cell stromal checkpoints

JOURNAL OF IMMUNOLOGY

IF3.4

2025-11-010

PRE

Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid Tumors

MOLECULAR CANCER THERAPEUTICS

IF5.5

2024-04-223

PRE

Pharmacodynamic and predictive biomarker results from the phase I dose escalation study of NGM707, an ILT2/ILT4 dual antagonist antibody, in patients with advanced solid tumors

CANCER RESEARCH

IF16.6

2024-03-220

PRE

A target discovery pipeline identified ILT3 as a target for immunotherapy of multiple myeloma

CELL REPORTS MEDICINE

IF10.6

2023-07-0114

OAAI

BLOCKADE OF HUMAN LILRB4/ILT3 INHIBITS THE FORMATION OF LUNG METASTASIS IN MELANOMA MODEL

JOURNAL FOR IMMUNOTHERAPY OF CANCER

IF10.6

2022-11-070

OA

Hypoxia-inducible factor a subunits regulate Tie2-expressing macrophages that influence tumor oxygen and perfusion in murine breast cancer (vol 205, 2301, 2020)

JOURNAL OF IMMUNOLOGY

IF3.4

2020-12-010

OAAI

Hypoxia-Inducible Factor a Subunits Regulate Tie2-Expressing Macrophages That Influence Tumor Oxygen and Perfusion in Murine Breast Cancer

JOURNAL OF IMMUNOLOGY

IF3.4

2020-10-1511

OAAI

Fcγ Receptor-induced Soluble Vascular Endothelial Growth Factor Receptor-1 (VEGFR-1) Production Inhibits Angiogenesis and Enhances Efficacy of Anti-tumor Antibodies

JOURNAL OF BIOLOGICAL CHEMISTRY

IF3.9

2013-09-0113

OAAI

Stabilization of HIF-2α Induces sVEGFR-1 Production from Tumor-Associated Macrophages and Decreases Tumor Growth in a Murine Melanoma Model

JOURNAL OF IMMUNOLOGY

IF3.4

2012-09-1573

OA

Cetuximab therapy in head and neck cancer: Immune modulation with interleukin-12 and other natural killer cell-activating cytokines

IF2.7

2012-09-0158

OAAI

Hypoxia-Inducible Factor-2α Regulates GM-CSF-Derived Soluble Vascular Endothelial Growth Factor Receptor 1 Production from Macrophages and Inhibits Tumor Growth and Angiogenesis

JOURNAL OF IMMUNOLOGY

IF3.4

2011-08-1576

OAAI

IL-12 Enhances the Antitumor Actions of Trastuzumab via NK Cell IFN-γ Production

JOURNAL OF IMMUNOLOGY

IF3.4

2011-03-1598

OAAI

A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies

MOLECULAR CANCER THERAPEUTICS

IF5.5

2009-11-10100

OAAI

A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab

BREAST CANCER RESEARCH AND TREATMENT

IF3

2008-12-0340

OAAI

The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor-positive tumor cells is enhanced by cytokines

CLINICAL CANCER RESEARCH

IF10.2

2007-11-01147

PREAI

Interferon α and CPG oligodeoxynucleotides elicit additive immunostimulatory and antitumor effects

IF2.7

2006-08-0113

PREAI

Interleukin-21 enhances NK cell activation in response to antibody-coated targets

JOURNAL OF IMMUNOLOGY

IF3.4

2006-07-01131

OAAI

Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells

CANCER RESEARCH

IF16.6

2006-01-05157

OAAI

A phase I trial of interleukin-12 with trastuzumab and paclitaxel for HER2-overexpressing malignancies

JOURNAL OF IMMUNOTHERAPY

IF2.9

2005-11-011

PREAI

Src homology 2-containing inositol 5′-phosphatase 1 negatively regulates IFN-γ production by natural killer cells stimulated with antibody-coated tumor cells and interleukin-12

CANCER RESEARCH

IF16.6

2005-10-0327

PREAI